Hikma Pharmaceuticals PLC HIK shares advanced 1.13% to £23.18 Monday, on what proved to be an all-around favorable trading ...

Hik­ma Phar­ma­ceu­ti­cals is ask­ing the US Supreme Court to re­view a gener­ic drug la­bel­ing rul­ing that it says will ...

PLC (LSE: HIK), a global pharmaceutical company, is set to announce its financial results for the year ending December 31, 2024, on Wednesday, February 26, 2025. The company will make a recording of ...

Investing.com -- Shares of Hikma Pharmaceuticals (OTC:HKMPY) (LON:HIK) jumped on Thursday after the company raised its full-year guidance, buoyed by robust performance in its Branded and Generics ...

Hikma Pharmaceuticals (LON:HIK – Free Report) had its price objective lifted by Berenberg Bank from GBX 2,400 ($29.74) to GBX 2,560 ($31.73) in a research note published on Wednesday morning, ...

Stock pickers are generally looking for stocks that will outperform the broader market. And the truth is, you can ...

Hikma’s US subsidiary, West-Ward Pharmaceuticals, formerly Boehringer Ingelheim’s US generic business, Roxane, will be responsible for development. Vectura will complete the formulation ...

Hikma Pharmaceuticals' corporate investment arm Hikma Ventures has launched a $30 million digital health fund in Jordan, focusing on therapeutic and diagnostic start-ups. The company's roots are ...

Hikma recently received the Food and Drug Administration’s permission for a new generic, and the company also launched two new generic products. The FDA approved Hikma's first generic ...

Hikma Pharmaceuticals PLC hit a new 52-week high, surpassing its previous peak of £23.14, which the company achieved on ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...